샘플 요청 목록

 카트 문의
시장보고서
상품코드
1579790

수니티닙 말레이트 시장

Sunitinib Malate
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 193 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

스니티닙 말레이트 세계 시장은 2030년까지 2억 800만 달러에 달할 것으로 예상됩니다

2023년 1억 910만 달러로 추정되는 수니티닙 말레이트 세계 시장은 2030년에는 2억 800만 달러에 달할 것으로 예상되며, 2023-2030년간 9.7%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 이 보고서에서 분석한 부문 중 하나인 순도 99% 초순수 니니티닙 말레이트은 CAGR 10.6%를 기록하여 분석 기간 종료 시점에 1억 900만 달러에 도달할 것으로 예상됩니다. 순도 98% 이상의 수니티닙 말레이트 부문은 분석 기간 동안 9.3%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 추정됩니다.

미국 시장은 3,190만 달러로 추정, 중국은 CAGR 8.7%로 성장 전망

미국의 수니티닙 말레이트 시장은 2023년 3,190만 달러 규모에 달할 것으로 예상됩니다. 세계 2위의 경제 대국인 중국은 분석 기간인 2023년부터 2030년까지 연평균 8.7%의 성장률을 보이며 2030년에는 3,530만 달러 규모에 도달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 8.6%와 7.7%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 유럽에서는 독일이 약 7.5%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

세계 수니티닙 링고네이트 시장 - 주요 동향 및 촉진요인 요약

스니티닙 말레이트이 암 표적 치료제의 핵심 기업인 이유는 무엇인가?

경구용 멀티키나아제 억제제인 수니티닙 말레이트은 신세포암(RCC), 위장관 간질 종양(GIST) 등 다양한 유형의 암 치료에 매우 중요한 역할을 하고 있습니다. 수니티닙은 표적치료제의 중요한 약제 중 하나로, 혈관신생, 증식, 전이 등 종양 성장에 관여하는 여러 경로를 억제하는 방식으로 작용합니다. 수니티닙은 진행성 신장암 및 기타 악성 종양 치료에 효과적이라는 FDA 승인을 받아 기존 화학요법이 효과가 없는 환자들에게 생명줄을 제공합니다. 혈관내피성장인자(VEGFR)와 혈소판유래성장인자수용체(PDGFR)를 억제하는 능력은 수니티닙을 표적항암제 시장의 핵심으로 자리매김하고 있습니다. 암 발병률 증가와 맞춤의료에 대한 수요 증가는 수니티닙의 암 분야에서의 채택을 촉진하고 있습니다.

스니티닙 말레이트의 미래를 바꿀 혁신은 무엇인가?

최근 정밀의료의 발전으로 수니티닙은 희귀암과 난치성 암 치료에 새로운 길을 열어가고 있습니다. 수니티닙과 다른 면역요법을 결합하여 치료 효과를 높이고 약제 내성을 극복하기 위한 연구가 주목받고 있습니다. 또한, 바이오마커의 개발로 암 전문의가 수니티닙 치료가 가장 효과적인 환자를 식별할 수 있게 되어 치료 성적이 향상되고 있습니다. 현재 진행 중인 임상시험에서는 수니티닙과 체크포인트 억제제와의 병용투여가 검토되고 있으며, 환자의 생존율 연장에 있어 유망한 결과를 보이고 있습니다. 그러나 약제 내성, 고혈압, 피로 등의 부작용으로 인해 수니티닙의 효능을 유지하면서 안전성 프로파일을 개선하기 위한 추가 연구가 진행되고 있습니다.

어떤 시장 세분화가 수니티닙 말레이트을 주도하고 있는가?

스니티닙은 진행성 및 전이성 신세포암(RCC)의 1차 치료제로서 신세포암(RCC)이 여전히 가장 큰 시장으로 남아있습니다. 수니티닙은 위장관 간질 종양(GIST) 치료 시장에서도 특히 이마티닙에 반응하지 않는 환자들 사이에서 인기를 얻고 있습니다. 지역별로는 북미가 높은 암 발병률, 유리한 상환 정책, 강력한 제약 인프라로 인해 가장 큰 시장 점유율을 차지하고 있습니다. 유럽은 암 치료와 임상연구의 발전에 힘입어 근소한 차이로 그 뒤를 잇고 있습니다. 반면, 아시아태평양의 신흥 시장은 암 발병률 증가와 의료 서비스 접근성 향상으로 인해 수요가 급증하고 있습니다.

스니티닙 말레이트 시장의 성장 원동력은?

스니티닙 말레이트 시장의 성장은 신세포암과 위장관 간질종양 발병률 증가, 표적치료제 채택 증가, 정밀 종양학의 발전 등 여러 요인에 의해 주도되고 있습니다. 암 연구에 대한 투자 확대와 병용요법 개발은 특히 전이성 암에서 약물의 적용을 확대하고 있습니다. 또한, 희귀암에 대한 수니티닙의 승인 확대와 신흥 시장에서의 임상시험 증가는 시장 침투를 촉진하고 있습니다. 신흥국 시장의 의료비 지출 증가와 암 치료 접근성 향상으로 시장 확대가 더욱 가속화되고 있습니다.

조사 대상 기업 예시(주목받는 44개사)

  • Active Biotech AB
  • Astellas Pharma, Inc.
  • Bristol-Myers Squibb Company
  • Changzhou Highassay Chemical Co., Ltd
  • Dendreon Pharmaceuticals LLC
  • Ferring Pharmaceuticals Inc
  • Hefei Home Sunshine Pharmaceutical Technology Co.
  • Medichem, S.A.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

    목차

    제1장 조사 방법

    제2장 주요 요약

    • 시장 개요
    • 주요 기업
    • 시장 동향과 촉진요인
    • 세계 시장 전망

    제3장 시장 분석

    • 미국
    • 캐나다
    • 일본
    • 중국
    • 유럽
    • 프랑스
    • 독일
    • 이탈리아
    • 영국
    • 기타 유럽
    • 아시아태평양
    • 기타 지역

    제4장 경쟁

    LSH 24.11.01

    Global Sunitinib Malate Market to Reach US$208.0 Million by 2030

    The global market for Sunitinib Malate estimated at US$109.1 Million in the year 2023, is expected to reach US$208.0 Million by 2030, growing at a CAGR of 9.7% over the analysis period 2023-2030. Above 99% Purity Sunitinib Malate, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$109.0 Million by the end of the analysis period. Growth in the Above 98% Purity Sunitinib Malate segment is estimated at 9.3% CAGR over the analysis period.

    The U.S. Market is Estimated at US$31.9 Million While China is Forecast to Grow at 8.7% CAGR

    The Sunitinib Malate market in the U.S. is estimated at US$31.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$35.3 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.6% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

    Global Sunitinib Malate Market - Key Trends and Drivers Summarized

    Why Is Sunitinib Malate a Key Player in Targeted Cancer Therapies?

    Sunitinib Malate, an oral multi-kinase inhibitor, plays a pivotal role in the treatment of various types of cancer, including renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST). As one of the key drugs in targeted therapy, Sunitinib works by inhibiting multiple pathways involved in tumor growth, including angiogenesis, proliferation, and metastasis. Approved by the FDA for its efficacy in treating advanced kidney cancer and other malignancies, Sunitinib offers a lifeline for patients who do not respond well to conventional chemotherapy. Its ability to block vascular endothelial growth factors (VEGFR) and platelet-derived growth factor receptors (PDGFR) has positioned it as a cornerstone in the targeted oncology market. The rising incidence of cancer and the growing demand for personalized medicine have driven the adoption of Sunitinib in oncology.

    What Are the Innovations Shaping the Future of Sunitinib Malate?

    Recent advancements in precision medicine have opened up new avenues for Sunitinib Malate in the treatment of rare and hard-to-treat cancers. Research is focusing on combining Sunitinib with other immunotherapies to enhance treatment efficacy and overcome drug resistance. Additionally, the development of biomarkers is helping oncologists identify patients who would benefit the most from Sunitinib therapy, thus improving treatment outcomes. Ongoing clinical trials are exploring its applications in combination with checkpoint inhibitors, showing promising results in extending patient survival rates. However, challenges such as drug resistance and side effects like hypertension and fatigue have spurred further research into improving the safety profile of Sunitinib without compromising its effectiveness.

    Which Market Segments Are Leading for Sunitinib Malate?

    The largest segment remains renal cell carcinoma (RCC), as Sunitinib is a first-line treatment for advanced and metastatic forms of this cancer. The drug is also gaining traction in the gastrointestinal stromal tumor (GIST) treatment market, particularly among patients who do not respond to imatinib. Regionally, North America holds the largest market share due to high cancer prevalence, favorable reimbursement policies, and a strong pharmaceutical infrastructure. Europe follows closely, driven by advancements in cancer treatment and clinical research. Meanwhile, emerging markets in Asia-Pacific are witnessing rapid growth in demand, fueled by increasing cancer rates and improving healthcare access.

    What Is Driving Growth in the Sunitinib Malate Market?

    The growth in the Sunitinib Malate market is driven by several factors, including the rising incidence of renal cell carcinoma and gastrointestinal stromal tumors, increasing adoption of targeted therapies, and advancements in precision oncology. Growing investments in cancer research and the development of combination therapies are expanding the drug’s application, particularly in metastatic cancers. Additionally, the expanding approval of Sunitinib for rare cancer indications, along with the growth of clinical trials in emerging markets, is boosting market penetration. The increasing healthcare expenditure and enhanced access to oncology treatments in developing regions are further accelerating market expansion.

    Select Competitors (Total 44 Featured) -

    • Active Biotech AB
    • Astellas Pharma, Inc.
    • Bristol-Myers Squibb Company
    • Changzhou Highassay Chemical Co., Ltd
    • Dendreon Pharmaceuticals LLC
    • Ferring Pharmaceuticals Inc
    • Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.
    • Medichem, S.A.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.

    TABLE OF CONTENTS

    I. METHODOLOGY

    II. EXECUTIVE SUMMARY

    • 1. MARKET OVERVIEW
      • Influencer Market Insights
      • World Market Trajectories
      • Global Economic Update
      • Sunitinib Malate - Global Key Competitors Percentage Market Share in 2024 (E)
      • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • 2. FOCUS ON SELECT PLAYERS
    • 3. MARKET TRENDS & DRIVERS
      • Rising Prevalence of Cancer Drives Demand for Sunitinib Malate in Oncology Treatments
      • Expansion of Targeted Therapies in Cancer Treatment Spurs Growth in Sunitinib Malate Market
      • Increased FDA Approvals for New Cancer Indications Expands Addressable Market Opportunity
      • Advancements in Precision Medicine Strengthen the Business Case for Sunitinib Malate
      • Rising Demand for Personalized Cancer Treatments Generates Market Growth
      • Emerging Clinical Trials for Combination Therapies Propels Market Competitiveness
      • Challenges Related to Drug Resistance in Cancer Treatments Create Opportunities for New Developments
      • Rising Investments in Cancer Research Accelerates Demand for Targeted Therapies
      • Increasing Focus on Orphan Drug Development Throws Spotlight on Sunitinib Malate
      • Growing Application in Metastatic Cancer Treatments Sustains Market Growth
      • Emergence of Biosimilars in Oncology Pharmaceuticals Creates Competitive Pressures
      • Growing Geriatric Population with High Cancer Susceptibility Propels Demand for Sunitinib Malate
      • Rising Healthcare Expenditure in Emerging Economies Boosts Market Penetration
    • 4. GLOBAL MARKET PERSPECTIVE
      • TABLE 1: World Sunitinib Malate Market Analysis of Annual Sales in US$ for Years 2014 through 2030
      • TABLE 2: World Recent Past, Current & Future Analysis for Sunitinib Malate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
      • TABLE 3: World 7-Year Perspective for Sunitinib Malate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
      • TABLE 4: World Recent Past, Current & Future Analysis for Above 99% Purity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
      • TABLE 5: World 7-Year Perspective for Above 99% Purity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
      • TABLE 6: World Recent Past, Current & Future Analysis for Above 98% Purity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
      • TABLE 7: World 7-Year Perspective for Above 98% Purity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
      • TABLE 8: World Recent Past, Current & Future Analysis for Above 97% Purity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
      • TABLE 9: World 7-Year Perspective for Above 97% Purity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
      • TABLE 10: World Recent Past, Current & Future Analysis for Pancreatic Neuroendocrine Tumor Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
      • TABLE 11: World 7-Year Perspective for Pancreatic Neuroendocrine Tumor Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
      • TABLE 12: World Recent Past, Current & Future Analysis for Gastrointestinal Stromal Tumor Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
      • TABLE 13: World 7-Year Perspective for Gastrointestinal Stromal Tumor Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
      • TABLE 14: World Recent Past, Current & Future Analysis for Kidney Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
      • TABLE 15: World 7-Year Perspective for Kidney Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

    III. MARKET ANALYSIS

    • UNITED STATES
      • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
      • TABLE 16: USA Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 17: USA 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
      • TABLE 18: USA Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 19: USA 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
    • CANADA
      • TABLE 20: Canada Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 21: Canada 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
      • TABLE 22: Canada Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 23: Canada 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
    • JAPAN
      • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
      • TABLE 24: Japan Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 25: Japan 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
      • TABLE 26: Japan Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 27: Japan 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
    • CHINA
      • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
      • TABLE 28: China Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 29: China 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
      • TABLE 30: China Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 31: China 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
    • EUROPE
      • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
      • TABLE 32: Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
      • TABLE 33: Europe 7-Year Perspective for Sunitinib Malate by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
      • TABLE 34: Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 35: Europe 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
      • TABLE 36: Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 37: Europe 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
    • FRANCE
      • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
      • TABLE 38: France Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 39: France 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
      • TABLE 40: France Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 41: France 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
    • GERMANY
      • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
      • TABLE 42: Germany Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 43: Germany 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
      • TABLE 44: Germany Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 45: Germany 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
    • ITALY
      • TABLE 46: Italy Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 47: Italy 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
      • TABLE 48: Italy Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 49: Italy 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
    • UNITED KINGDOM
      • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
      • TABLE 50: UK Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 51: UK 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
      • TABLE 52: UK Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 53: UK 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
    • REST OF EUROPE
      • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 55: Rest of Europe 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
      • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 57: Rest of Europe 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
    • ASIA-PACIFIC
      • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
      • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 59: Asia-Pacific 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
      • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 61: Asia-Pacific 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
    • REST OF WORLD
      • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 63: Rest of World 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
      • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
      • TABLE 65: Rest of World 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030

    IV. COMPETITION

    • 샘플 요청 목록
    0 건의 상품을 선택 중
    목록 보기
    전체삭제